![Ingrid Boyes](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Loopbaan van Ingrid Boyes
Eerdere bekende functies van Ingrid Boyes
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MYOKARDIA, INC. | Human Resources Officer | - | 01-01-2020 |
Genentech, Inc.
![]() Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Human Resources Officer | 01-01-2006 | 01-01-2009 |
Corporate Officer/Principal | 01-01-1999 | 01-01-2009 |
Opleiding van Ingrid Boyes
University of San Francisco | Undergraduate Degree |
Notre Dame de Namur University | Masters Business Admin |
Statistieken
Internationaal
Verenigde Staten | 5 |
Operationeel
Human Resources Officer | 2 |
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Sectoraal
Health Technology | 3 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Genentech, Inc.
![]() Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
MyoKardia, Inc.
![]() MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
- Beurs
- Insiders
- Ingrid Boyes
- Ervaring